Test Code SBULB Spinobulbar Muscular Atrophy (Kennedy Disease), Molecular Analysis, Varies
Useful For
Molecular confirmation of clinically suspected cases of sporadic or familial spinobulbar muscular atrophy (SBMA)
Presymptomatic testing for individuals with a family history of SBMA and a documented expansion in the androgen receptor (AR) gene
Special Instructions
Method Name
Polymerase Chain Reaction (PCR)
Reporting Name
Spinobulbar Musc Atrophy, Kennedy'sSpecimen Type
VariesShipping Instructions
Specimen preferred to arrive within 96 hours of draw.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send specimen in original tube.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Frozen | |||
Refrigerated |
Reject Due To
All specimens will be evaluated by Mayo Clinic Laboratories for test suitability.Clinical Information
X-linked spinal and bulbar muscular atrophy (spinobulbar muscular atrophy: SBMA; or Kennedy disease) is characterized by onset of progressive muscle weakness, atrophy, and fasciculations typically in the fourth or fifth decade of life. Affected patients also have signs of androgen insensitivity such as gynecomastia, reduced fertility, and testicular atrophy. The clinical severity and age at onset can be quite variable, even within families. Because this is an X-linked disease, males manifest this disorder and females are generally asymptomatic carriers. However, there have been reports of female carriers who exhibit symptoms such as muscle weakness and cramping.
SBMA is caused by an expansion of the CAG trinucleotide repeat in exon 1 of the human androgen receptor (AR) gene. This trinucleotide repeat is polymorphic in the general population, with the number of repeats ranging from 11 to 34. The number of repeats found in affected individuals can range from 38 to 62. There is no consensus as to the clinical significance of alleles of 35 CAG repeats and literature suggests that alleles of 36 to 37 CAG repeats may be associated with reduced penetrance. As with other trinucleotide repeat disorders, anticipation is frequently observed and larger CAG expansions are associated with earlier onset and a more rapid clinical progression.
Reference Values
Normal alleles: 11-34 CAG repeats
Abnormal alleles: 36-62 CAG repeats
An interpretive report will be provided.
Interpretation
An interpretive report will be provided.
Cautions
For predictive testing, it is important to first document the presence of a CAG-repeat amplification in the androgen receptor (AR) gene in an affected family member to confirm that molecular expansion is the underlying mechanism of disease in the family.
We strongly recommend that patients undergoing predictive testing receive genetic counseling both prior to testing and after results are available.
Predictive testing of an asymptomatic child is not recommended.
Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete..
Current evidence suggests that the majority of individuals with spinobulbar muscular atrophy (SBMA) have a CAG-repeat expansion. However, we cannot eliminate the possibility that another type of mutation not detected by our assay is present within the AR gene.
Method Description
Direct mutation analysis. A PCR-based assay is used to detect amplification-type mutations (CAG-repeat expansion) within the AR gene. (Doyu M, Sobue G, Mukai E, et al: Severity of X-linked recessive bulbospinal neuronopathy correlated with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992;31:707-710)
Day(s) Performed
Tuesday
Report Available
14 to 21 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81204-AR (androgen receptor)(eg, spinal and bulba muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
SBULB | Spinobulbar Musc Atrophy, Kennedy's | 35359-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
53341 | Result Summary | 50397-9 |
53342 | Result | 82939-0 |
53343 | Interpretation | 69047-9 |
53344 | Reason for Referral | 42349-1 |
53345 | Specimen | 31208-2 |
53346 | Source | 31208-2 |
53348 | Released By | 18771-6 |
Testing Algorithm
For more information see Inherited Motor Neuron Disease and Dementia Testing Algorithm